These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
729 related articles for article (PubMed ID: 29807949)
1. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Lee EK; Mui WH; Chan AW; Tung Y; Wong FC Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949 [TBL] [Abstract][Full Text] [Related]
5. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience. Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277 [TBL] [Abstract][Full Text] [Related]
6. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression. Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924 [TBL] [Abstract][Full Text] [Related]
7. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. Ying J; Wang CJ; Yan J; Liauw SL; Straka C; Pistenmaa D; Xie XJ; Lotan Y; Roehrborn C; Kim DN Am J Clin Oncol; 2017 Dec; 40(6):612-620. PubMed ID: 26165416 [TBL] [Abstract][Full Text] [Related]
8. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736 [TBL] [Abstract][Full Text] [Related]
9. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358 [TBL] [Abstract][Full Text] [Related]
10. Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy. Scharl S; Gartner L; Böhmer DHG; Siegmann A; Thamm R; Krafcsik M; Mayer B; Zips D; Ruf C; Wiegel T Radiother Oncol; 2024 Nov; 200():110476. PubMed ID: 39147035 [TBL] [Abstract][Full Text] [Related]
11. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate. Budäus L; Schiffmann J; Graefen M; Huland H; Tennstedt P; Siegmann A; Böhmer D; Budach V; Bartkowiak D; Wiegel T Strahlenther Onkol; 2017 Sep; 193(9):692-699. PubMed ID: 28470414 [TBL] [Abstract][Full Text] [Related]
12. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539 [TBL] [Abstract][Full Text] [Related]
13. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Kupelian PA; Katcher J; Levin HS; Klein EA Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811 [TBL] [Abstract][Full Text] [Related]
14. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399 [TBL] [Abstract][Full Text] [Related]
16. Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy. Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469 [No Abstract] [Full Text] [Related]
17. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700 [TBL] [Abstract][Full Text] [Related]
18. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. Stephenson AJ; Scardino PT; Kattan MW; Pisansky TM; Slawin KM; Klein EA; Anscher MS; Michalski JM; Sandler HM; Lin DW; Forman JD; Zelefsky MJ; Kestin LL; Roehrborn CG; Catton CN; DeWeese TL; Liauw SL; Valicenti RK; Kuban DA; Pollack A J Clin Oncol; 2007 May; 25(15):2035-41. PubMed ID: 17513807 [TBL] [Abstract][Full Text] [Related]
19. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy. Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967 [TBL] [Abstract][Full Text] [Related]
20. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy. Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]